Loading...
Market
Financial status of Mammoth Biosciences one year after Regeneron's investment
3
Resolution / Starting Odds
Profitable • 25%
Break-even • 25%
Minor losses • 25%
Significant losses • 25%
Financial statements, press releases, or major financial news outlets
Story
Regeneron Invests $100M in Mammoth for CRISPR-Based Gene Editing Therapies
Apr 25, 2024, 11:30 AM
Regeneron Pharmaceuticals has announced a significant expansion into gene editing by partnering with Mammoth Biosciences. The collaboration aims to research, develop, and commercialize CRISPR-based gene editing therapies for various diseases, targeting multiple tissues and cell types. Regeneron will make a substantial financial commitment, including a $5 million upfront payment and a $95 million equity investment in the CRISPR startup, totaling $100 million. This move is part of Regeneron's broader strategy to deepen its capabilities in genetic medicines, including a recent acquisition in cell therapy and ongoing partnerships focused on developing treatments for rare diseases like transthyretin amyloidosis. Mammoth, which previously developed CRISPR technology for COVID-19 diagnostics, has shifted focus to smaller DNA-cutting enzymes that could be more easily delivered into tissues across the body.
View original story
Similar markets
Regeneron • 50%
Mammoth Biosciences • 50%
Increase in net income • 33%
Decrease in net income • 33%
No significant change in net income • 34%
$0-100 million • 25%
$101-500 million • 25%
$501 million - $1 billion • 25%
Over $1 billion • 25%
1-2 diseases • 33%
3-4 diseases • 33%
5 or more diseases • 33%
Profitable • 25%
Break-even • 25%
Minor losses • 25%
Significant losses • 25%
Positive net income • 33%
Break-even • 33%
Negative net income • 33%
Approval • 33%
Request for additional data • 33%
Rejection • 33%
Significant financial loss • 33%
Minimal financial impact • 33%
Financial gain • 34%